CAMBRIDGE, Mass.– Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, announced promising preclinical results for VT-1908, the first topical formulation of mycophenolate developed for the treatment of uveitis. Findings were presented at the Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics.
Uveitis, an inflammation of part of the eye, is linked to 30,000 new cases of legal blindness each year in the United States, representing a potential $3 billion market by 2032. Current treatments rely on steroids, which are often ineffective and associated with complications such as cataracts and increased eye pressure leading to glaucoma. Vyome’s VT-1908 aims to provide a safer, effective alternative through topical administration. The broader global market for ocular inflammation treatments is expected to exceed $20 billion by 2030.
In preclinical models of anterior uveitis, the most common form of the disease, twice-daily application of VT-1908 eyedrops achieved the desired drug concentration in the anterior chamber of the eye and significantly reduced uveitis scores (P<0.001). The efficacy of VT-1908 was comparable to that of clinically used steroids.
“Inflammation is one of the biggest problems of our time, often linked to the immune system, and we are addressing the root cause in tangible and specific applications in the eye,” said Dr. Shiladitya Sengupta, Co-Founder of Vyome and Associate Professor of Medicine at Harvard Medical School. “The fact that VT-1908 is as effective as a steroid is exciting because it offers the potential to replace steroids, which are associated with a number of complications. Our results give hope that a breakthrough treatment may soon be available for patients with uveitis, and they strongly support advancing VT-1908 into the clinic.”
Venkat Nelabhotla, CEO of Vyome, added, “We are encouraged by these efficacy signals and plan to initiate a Phase 1/2 clinical trial in the second half of 2026. While uveitis will be our near-term focus, our long-term vision is to replace steroids in treating ocular inflammation, a potential $20 billion market. This program reflects our broader strategy of building a portfolio targeting chronic immune-inflammation.”
